In March, ANVISA granted regulatory approval for Uplyso to Pfizer Inc., of New York, Protalix' development partner

Intercept Pharmaceuticals Inc., of New York, priced an underwritten public offering of about 1.7 million shares of its common stock at a price of $33.01 per share, for gross proceeds of about $57 million

Intellect Neurosciences Inc., of New York, said its board engaged Evli Corporate Finance to assist the firm with the exploration of strategic alternatives

New York-based Royalty Pharma has, arguably, done the same thing

Covidien expects to complete the distribution of Mallinckrodt ordinary shares after the close of trading on the New York Stock Exchange on June 28

Intercept Pharmaceuticals Inc., of New York, commenced an underwritten public offering of about 1.7 million shares of its common stock

New York-based Royalty Pharma has, arguably, done the same thing

Bristol-Myers Squibb Co., of New York, and Abbvie Inc., of Chicago, announced updated efficacy and safety data from a small, randomized Phase II, open-label study in patients with previously treated multiple myeloma that evaluated two doses of the investigational monoclonal antibody elotuzumab (10 mg/kg and 20 mg/kg) in combination with lenalidomide and low-dose dexamethasone

and New York-based Pfizer Inc

Intercept Pharmaceuticals Inc., of New York, commenced an underwritten public offering of about 1.7 million shares of its common stock

Bristol-Myers Squibb Co. (BMS), of New York, and Simcere Pharmaceutical Group, of Nanjing, China, expanded their strategic relationship formed in 2010

Researchers from New York University have discovered how fingertips regenerate, and why whole fingers don't

As part of that process Royalty Pharma, of New York, will be invited to participate...Intellicell BioSciences Inc., of New York, said its cellular laboratory facility underwent a thorough inspection by the FDA

New York) LAMA/LABA Aclidinium bromide and formoterol fumarate delivered in the Pressair inhaler Phase III data demonstrated statistically significant Phase III data demonstrated statistically significant improvements with the 400/12 mcg combination in change from baseline for the co-primary endpoints of forced expiratory volume at one hour post-dose 5/2/13 Astellas Pharma Europe BV (Meppel, the Netherlands) Vesomni Solifenacin + tamsulosin Benign prostatic hyperplasia The Dutch Medicines

5/23/13 GASTROINTESTINAL Synergy Pharmaceuticals Inc. (New York) Plecanatide A guanylate cyclase-C agonist Chronic idiopathic constipation Showed it demonstrated statistically significant improvement vs

personalized cancer vaccine Advanced ovarian cancer Interim Phase II data showed a positive tumor immune response as measured by enzyme-linked immunospot analysis in 71% of patients 5/16/13 Gtx Inc. (Memphis, Tenn.) Gtx-024 A selective androgen receptor modulator Metastatic breast cancer Started a Phase II study 5/1/13 Izun Pharmaceuticals Corp. (New York) IZN-6N4 Oral rinse Oral mucositis in head and neck cancer Expanded its ongoing Phase II trial to two additional centers, Memorial Sloan

For Phase III drugs, this could be a year of buyers' market," Neel Patel, director of New York-based Campbell Alliance, said at the conference

Ohr Pharmaceutical Inc., of New York, said it received confirmation that its application to list on Nasdaq was approved...Zealand Pharma A/S, of Copenhagen, signed a collaboration agreement with D.E. Shaw Research LLC., of New York, to combine Shaw's molecular dynamics simulations with Zealand's capabilities in peptide drug development

and Sun Pharmaceutical Industries Ltd. $2.15 billion in a settlement reached with Pfizer Inc., of New York, and Nycomed A/S, now part of Takeda Pharmaceutical Co